Mechanism
Food reward and hedonic eating
Eating is partly driven by reward — wanting and liking certain foods. GLP-1 receptor agonists appear to reduce the hedonic pull of palatable foods in addition to reducing hunger. This may explain reports of reduced cravings and altered preferences during therapy.
Plain-English explanation
Eating is partly driven by reward — wanting and liking certain foods. GLP-1 receptor agonists appear to reduce the hedonic pull of palatable foods in addition to reducing hunger. This may explain reports of reduced cravings and altered preferences during therapy.
Research-level explanation
Best supported by functional MRI studies of liraglutide and semaglutide in adults with obesity, complemented by ad-libitum eating designs. Translation to formal addiction or eating-disorder indications remains investigational.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| GLP-1 RAs can be used to treat addiction. | Trials in alcohol-use disorder and other addictions are exploratory at the time of review; no GLP-1 RA is licensed for an addiction indication. |
Safety relevance
Psychiatric safety tracking; some patients report mood-related changes during therapy and these are subject to ongoing pharmacovigilance review.
- Hedonic-eating effects in research populations do not establish efficacy outside their studied indications.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site